Role and mechanism of thrombospondin in response to beta blocker therapy in patients with congestive heart failure

点击翻译按钮获取中文摘要

We evaluated Ala523Thr polymorphism(G/A) and thrombospondin-1 plasma levels in nonischemic congestive heart failure patients before, 6, and 12 months after administration of beta blocker therapy and in normal healthy volunteers. There were no significant differences of thrombospondin-1 plasma levels between GG group and non GG group in normal healthy volunteers. No significant differences of thrombospondin-1 plasma levels were found between GG group and non GG group in nonischemic congestive heart failure patients. There were significant correlations between changes in BNP levels from before to 12 months after administration of beta blocker therapy and those in plasma thrombospondin-1 levels. Thrombospondin-1 may play a role in hemodynamic optimization at the chronic stage of nonischemic congestive heart failure.